MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis

Qiaozhu Su, Virender Kumar, Neetu Sud, Ram I Mahato

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Non-alcoholic fatty liver disease (NAFLD) increases the risk of various liver injuries, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis, and ultimately hepatocellular carcinoma (HCC). Ample evidence has suggested that aberrant expression of microRNAs (miRNAs) is functionally involved in the activation of cellular stress, inflammation and fibrogenesis in hepatic cells, including hepatocytes, Kupffer and hepatic stellate cells (HSCs), at different pathological stages of NAFLD and liver fibrosis. Here, we overview recent findings on the potential role of miRNAs in the pathogenesis of NAFLD, including lipotoxicity, oxidative stress, metabolic inflammation and fibrogenesis. We critically assess the literatures on both human subjects and animal models of NAFLD and liver fibrosis with miRNA dysregulation and their mechanisms of actions in liver damage. We further highlight the potential use of miRNA mimics or antimiRNAs as therapeutic approaches for the prevention and treatment of NAFLD and liver fibrosis.

Original languageEnglish (US)
Pages (from-to)54-63
Number of pages10
JournalAdvanced Drug Delivery Reviews
Volume129
DOIs
StatePublished - Apr 2018

Fingerprint

MicroRNAs
Liver Cirrhosis
Liver
Wounds and Injuries
Hepatocytes
Fibrosis
Inflammation
Hepatic Stellate Cells
Fatty Liver
Hepatocellular Carcinoma
Oxidative Stress
Animal Models
Non-alcoholic Fatty Liver Disease
Therapeutics

Keywords

  • AntimiRNAs
  • Lipotoxicity
  • Liver fibrosis
  • Metabolic inflammation
  • NAFLD
  • NASH
  • miRNAs

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis. / Su, Qiaozhu; Kumar, Virender; Sud, Neetu; Mahato, Ram I.

In: Advanced Drug Delivery Reviews, Vol. 129, 04.2018, p. 54-63.

Research output: Contribution to journalReview article

@article{5a634240f6d7429aa2ea0b3a78e76506,
title = "MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis",
abstract = "Non-alcoholic fatty liver disease (NAFLD) increases the risk of various liver injuries, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis, and ultimately hepatocellular carcinoma (HCC). Ample evidence has suggested that aberrant expression of microRNAs (miRNAs) is functionally involved in the activation of cellular stress, inflammation and fibrogenesis in hepatic cells, including hepatocytes, Kupffer and hepatic stellate cells (HSCs), at different pathological stages of NAFLD and liver fibrosis. Here, we overview recent findings on the potential role of miRNAs in the pathogenesis of NAFLD, including lipotoxicity, oxidative stress, metabolic inflammation and fibrogenesis. We critically assess the literatures on both human subjects and animal models of NAFLD and liver fibrosis with miRNA dysregulation and their mechanisms of actions in liver damage. We further highlight the potential use of miRNA mimics or antimiRNAs as therapeutic approaches for the prevention and treatment of NAFLD and liver fibrosis.",
keywords = "AntimiRNAs, Lipotoxicity, Liver fibrosis, Metabolic inflammation, NAFLD, NASH, miRNAs",
author = "Qiaozhu Su and Virender Kumar and Neetu Sud and Mahato, {Ram I}",
year = "2018",
month = "4",
doi = "10.1016/j.addr.2018.01.009",
language = "English (US)",
volume = "129",
pages = "54--63",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",

}

TY - JOUR

T1 - MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis

AU - Su, Qiaozhu

AU - Kumar, Virender

AU - Sud, Neetu

AU - Mahato, Ram I

PY - 2018/4

Y1 - 2018/4

N2 - Non-alcoholic fatty liver disease (NAFLD) increases the risk of various liver injuries, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis, and ultimately hepatocellular carcinoma (HCC). Ample evidence has suggested that aberrant expression of microRNAs (miRNAs) is functionally involved in the activation of cellular stress, inflammation and fibrogenesis in hepatic cells, including hepatocytes, Kupffer and hepatic stellate cells (HSCs), at different pathological stages of NAFLD and liver fibrosis. Here, we overview recent findings on the potential role of miRNAs in the pathogenesis of NAFLD, including lipotoxicity, oxidative stress, metabolic inflammation and fibrogenesis. We critically assess the literatures on both human subjects and animal models of NAFLD and liver fibrosis with miRNA dysregulation and their mechanisms of actions in liver damage. We further highlight the potential use of miRNA mimics or antimiRNAs as therapeutic approaches for the prevention and treatment of NAFLD and liver fibrosis.

AB - Non-alcoholic fatty liver disease (NAFLD) increases the risk of various liver injuries, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis, and ultimately hepatocellular carcinoma (HCC). Ample evidence has suggested that aberrant expression of microRNAs (miRNAs) is functionally involved in the activation of cellular stress, inflammation and fibrogenesis in hepatic cells, including hepatocytes, Kupffer and hepatic stellate cells (HSCs), at different pathological stages of NAFLD and liver fibrosis. Here, we overview recent findings on the potential role of miRNAs in the pathogenesis of NAFLD, including lipotoxicity, oxidative stress, metabolic inflammation and fibrogenesis. We critically assess the literatures on both human subjects and animal models of NAFLD and liver fibrosis with miRNA dysregulation and their mechanisms of actions in liver damage. We further highlight the potential use of miRNA mimics or antimiRNAs as therapeutic approaches for the prevention and treatment of NAFLD and liver fibrosis.

KW - AntimiRNAs

KW - Lipotoxicity

KW - Liver fibrosis

KW - Metabolic inflammation

KW - NAFLD

KW - NASH

KW - miRNAs

UR - http://www.scopus.com/inward/record.url?scp=85041927610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041927610&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2018.01.009

DO - 10.1016/j.addr.2018.01.009

M3 - Review article

C2 - 29391222

AN - SCOPUS:85041927610

VL - 129

SP - 54

EP - 63

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

ER -